Rallybio (NASDAQ:RLYB) Shares Up 1% – Time to Buy?

Rallybio Corporation (NASDAQ:RLYB) shares were up 1% on Monday . The stock traded as high as $16.15 and last traded at $15.89. Approximately 124,711 shares changed hands during trading, an increase of 214% from the average daily volume of 39,658 shares. The stock had previously closed at $15.73.

Analysts Set New Price Targets

A number of research analysts have weighed in on RLYB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Rallybio Price Performance

The company has a market cap of $85.57 million, a P/E ratio of -3.72 and a beta of -0.90. The stock has a fifty day moving average price of $15.45 and a two-hundred day moving average price of $10.09.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.21 million.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 10,200 shares of Rallybio stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the purchase, the insider directly owned 926,352 shares in the company, valued at $12,950,400.96. The trade was a 1.11% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have acquired 302,473 shares of company stock valued at $4,229,715. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. XTX Topco Ltd grew its position in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC grew its holdings in shares of Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. 90.34% of the stock is owned by institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.